ClinicalTrials.gg
RecruitingNCT06846606Updated Oct 16, 2026

Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

A Phase 1 interventional study of AUTX-703 in Relapsed Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory AML, sponsored by Auron Therapeutics, Inc.. Recruiting at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Auron Therapeutics, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.
Updated Oct 16, 2026Site recruiting status changedGo to Updates ↓
Phase
Phase 1
Study type
Interventional
Enrollment
69
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This Phase 1, multicenter, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of AUTX-703 administered orally in subjects with advanced hematologic malignancies.

Read the detailed description

This is a first-in-human, Phase 1, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of AUTX-703, an orally bioavailable lysine acetyltransferase 2A (KAT2A) and lysine acetyltransferase 2B (KAT2B) degrader, in participants with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The study consists of two parts: Part A (Dose Escalation) to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D), and Part B (Dose Optimization) to further evaluate safety, PK, PD and efficacy at selected dosages.

02

Conditions studied

  • Relapsed Acute Myeloid Leukemia (AML)
  • Refractory Acute Myeloid Leukemia (AML)
  • Relapsed/Refractory AML
  • Relapsed Myelodysplastic Syndromes
  • Refractory Myelodysplastic Syndromes
  • Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Keywords

  • AUTX-703
  • Relapsed Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Relapsed/Refractory AML
  • Acute Myeloid Leukemia
  • Relapsed Myelodysplastic Syndromes
  • Refractory Myelodysplastic Syndromes
  • KAT2A/B degrader
  • Myelodysplastic Syndromes
03

In context

Leukemia, Myeloid, Acute

3,667 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.

This study's planned enrollment of 69 is above the median of 40 across 3,005 interventional studies indexed under Leukemia, Myeloid, Acute.

Browse Leukemia, Myeloid, Acute studies →

Lead sponsor

This is the only study on the registry with Auron Therapeutics, Inc. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Participant must be ≥18 years of age
  2. Participant must have confirmed diagnosis as follows:

    R/R AML and has not achieved adequate response to, or cannot tolerate, all approved therapies known to be active for treatment of their disease OR R/R MDS with over 10% blasts in the bone marrow and has not achieved an adequate response to at least 4 cycles of a hypomethylating agent (HMA)- containing regimen or other treatment known to be active for their disease OR R/R AML or R/R MDS that has after a hematopoietic stem cell transplant ()

  3. Participant must be willing and able to comply with scheduled study visits and treatment plans.
  4. Participant must be willing to undergo all study procedures unless due to medical risk.
  5. Participant must have an (ECOG) performance status (PS) of 0-1
  6. Participant must have adequate hepatic function
  7. Participant must have adequate renal function
  8. Participant must have adequate cardiovascular function
  9. Participant must have a white blood cell (WBC) count ≤20 × 10⁹/L (with stable hydroxyurea use allowed)
  10. Participant must meet timing requirements with respect to prior therapy and surgery
  11. Participant must agree to use effective during the study and for the required post-treatment period: Males: Use condoms (even if vasectomized) during the study and for 90 days post-treatment. Females of : Use a combination of 1 highly effective and 1 effective method of contraception during the study and for 180 days post-treatment.

Key Exclusion Criteria:

  1. Participant is unable to provide and/or to follow protocol requirements.
  2. Participant has undergone chimeric antigen receptor T cell therapy or HSCT within 60 days of the first dose of study treatment or has active (GVHD)
  3. Participant has another that may interfere with diagnosis and treatment of R/R AML or R/R MDS.
  4. Participant has an active severe infection that requires anti-infective therapy or has an unexplained temperature of >38.5°C during screening visits or on their first day of study treatment.
  5. Participant has a known sensitivity to AUTX-703 or any of its components.
  6. Participant is taking systemic strong inhibitors or inducers within 14 days of the first dose of study treatment.
  7. Participant who are taking proton pump inhibitors should be switched to another acid-reducing agent such as an antacid or H2 blocker
  8. Participant is taking P-gp and breast cancer resistance protein (BCRP) inhibitors or inducers within 14 days of first dose of study treatment.
  9. Participant has active virus (HBV) or virus (HCV) infections with detectable viral load
  10. Participant has experienced AIDS related illness within the past 6 months or have detectable viral load.
  11. Participant has an uncontrolled intercurrent illness
  12. Participant has active Class III or IV cardiovascular disease within 6 months prior to the start of study treatment
  13. Participant is unable to tolerate the administration of oral medication or has GI dysfunction that would preclude adequate absorption, distribution, metabolism, or excretion of an oral medication
  14. Participant is pregnant or breastfeeding or is planning to become pregnant within 1 year of the start of study treatment
  15. Have a history of interstitial lung disease or pneumonitis.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
69 participants (estimated)

Study arms

  • Experimental
    Dose Escalation - Part A

    Participants will receive escalating dosages of AUTX-703 orally in tablet form once, twice or three times weekly to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D).

    Drug: AUTX-703

  • Experimental
    Dose Optimization - Part B, Dosage 1

    Participants will receive AUTX-703 at the first selected dosage determined from Part A, administered orally in tablet form either once, twice or three times weekly to further evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity at this specified dose.

    Drug: AUTX-703

  • Experimental
    Dose Optimization - Part B, Dosage 2

    Participants will receive AUTX-703 at the second selected dosage determined from Part A, administered orally in tablet form either once, twice or three times weekly to further evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity at this specified dose.

    Drug: AUTX-703

Interventions

  • DrugAUTX-703

    AUTX-703 administered orally

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events (AEs), Dose-Limiting Toxicities (DLTs), and Serious Adverse Events (SAEs)

    To assess the safety and tolerability of AUTX-703 by evaluating the incidence and severity of AEs, DLTs, SAEs, and AEs leading to treatment discontinuation.

    Time frame: From the first dose through 28 days after the last dose of study drug.

Secondary outcomes

  1. To Identify the Recommended Phase 2 Dose (RP2D) of AUTX-703

    To determine the RP2D of AUTX-703 based on safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity data.

    Time frame: From the first dose through 28 days after the last dose of study drug.

  2. Peak Plasma Concentration (Cmax)

    Time frame: From the first dose through the first treatment cycle (28 days)

  3. Time to Maximum Concentration (Tmax)

    Time frame: From the first dose through the first treatment cycle (28 days)

  4. Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity (AUCinf)

    Time frame: From the first dose through the first treatment cycle (28 days)

  5. Area Under the Plasma Concentration-Time Curve to the Last Measurable Concentration (AUClast)

    Time frame: From the first dose through the first treatment cycle (28 days)

  6. Elimination Half-Life (t½)

    Time frame: From the first dose through the first treatment cycle (28 days)

  7. Apparent Clearance (CL/F)

    Time frame: From the first dose through the first treatment cycle (28 days)

  8. Apparent Volume of Distribution (Vd/F)

    Time frame: From the first dose through the first treatment cycle (28 days)

  9. To characterize the PD of AUTX-703

    To evaluate changes in KAT2A and KAT2B levels in peripheral blood and bone marrow as markers of pharmacodynamic response

    Time frame: From the first dose through 28 days after the last dose of study drug

  10. AML: Complete remission (CR) rate

    Time frame: Up to 18 months

  11. AML: CR + CRh rate

    Time frame: Up to 18 months

  12. AML: Duration of CR

    Time frame: Up to 18 months

  13. AML: Duration of CR + CRh

    Time frame: Up to 18 months

  14. Objective response rate (ORR)

    Time frame: Up to 24 months

  15. AML: Duration of response (DOR)

    Time frame: Up to 18 months

  16. AML: Transfusion independence (TI) rate

    Time frame: Up to 18 months

  17. AML: Event free survival (EFS)

    Time frame: Up to 24 months

  18. AML: Overall survival (OS)

    Time frame: Up to 24 months

  19. MDS: Complete remission (CR) rate

    Time frame: Up to 18 months

  20. MDS: PR rate

    Time frame: Up to 18 months

  21. MDS: CR+PR rate

    Time frame: Up to 18 months

  22. MDS: Duration of CR

    Time frame: Up to 18 months

  23. MDS: Duration of PR

    Time frame: Up to 18 months

  24. MDS: Duration of CR+PR

    Time frame: Up to 18 months

  25. MDS: Event free survival (EFS)

    Time frame: Up to 24 months

  26. MDS: Overall survival (OS)

    Time frame: Up to 24 months

07

Study locations

9 of 9 sites recruiting
  • City of Hope National Medical Center
    Duarte, California 91010, United States
    Recruiting
  • H Lee Moffitt Cancer Center and Research Institute
    Tampa, Florida 33612, United States
    Recruiting
  • Roswell Park Comprehensive Cancer Center
    Buffalo, New York 14203, United States
    Recruiting
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10021, United States
    Recruiting
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27514, United States
    Recruiting
  • Ohio State University, The James Comprehensive Cancer
    Columbus, Ohio 43210, United States
    Recruiting
  • UPENN Perelman Center for Advanced Medicine
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
  • Sarah Cannon Center for Blood Cancer at TriStar Centennia
    Nashville, Tennessee 37203, United States
    Recruiting
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Apr 2027, 23 months after the start.

Of 183 industry-sponsored phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 62. This study's planned 23 months is below that.

Counting every sponsor, half of 488 studies reached it within 49 months; a quarter within 31 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2025
First posted
Feb 26, 2025
StartActual
May 1, 2025
Primary completionEst.
Apr 2027
CompletionEst.
Jun 2028
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites changed recruiting status (4 now recruiting)
Show 4 sites
  • H Lee Moffitt Cancer Center and Research Institute · Tampa, United StatesActive, not recruiting→Recruiting
  • Roswell Park Comprehensive Cancer Center · Buffalo, United StatesActive, not recruiting→Recruiting
  • Memorial Sloan Kettering Cancer Center · New York, United StatesActive, not recruiting→Recruiting
  • University of Texas MD Anderson Cancer Center · Houston, United StatesActive, not recruiting→Recruiting
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    4 sites changed recruiting status (4 now recruiting)
    Show 4 sites
    • H Lee Moffitt Cancer Center and Research Institute · Tampa, United StatesActive, not recruiting→Recruiting
    • Roswell Park Comprehensive Cancer Center · Buffalo, United StatesActive, not recruiting→Recruiting
    • Memorial Sloan Kettering Cancer Center · New York, United StatesActive, not recruiting→Recruiting
    • University of Texas MD Anderson Cancer Center · Houston, United StatesActive, not recruiting→Recruiting

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06846606
Lead sponsor
Auron Therapeutics, Inc.
Responsible party
Sponsor
First posted
Feb 26, 2025
Start date
May 1, 2025
Primary completion
Apr 2027 (estimated)
Completion
Jun 2028 (estimated)
Last update
Oct 16, 2026

Study contacts

Auron Clinical Trials
Contact
clinicaltrials@aurontx.com
617-514-2356

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion